Cover Image
市場調查報告書

輻射性皮炎:開發中產品分析

Radiodermatitis - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 335689
出版日期 內容資訊 英文 41 Pages
訂單完成後即時交付
價格
Back to Top
輻射性皮炎:開發中產品分析 Radiodermatitis - Pipeline Review, H2 2016
出版日期: 2016年11月16日 內容資訊: 英文 41 Pages
簡介

輻射性皮炎是放射線造成的皮膚發炎。依分割照射的範圍、能源種類、照射量等治療要素不同,患者肌膚上出現的症狀也有所不同。遺傳因素、皮膚狀態、併發症、營養狀態、年齡、人種、服藥、陽光照射、吸煙等要素都對輻射性皮炎的程度有莫大的影響。

本報告提供輻射性皮炎的治療藥開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

簡介

  • 調查範圍

輻射性皮炎概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

輻射性皮炎:企業開發中的治療藥

輻射性皮炎:大學/機關研究中的治療藥

輻射性皮炎:開發中產品概況

  • 臨床階段的產品
  • 初期階段的產品

輻射性皮炎:企業開發中的產品

輻射性皮炎:大學/機關研究中的產品

輻射性皮炎的治療藥的開發企業

  • ProCertus BioPharm Inc.
  • Reata Pharmaceuticals, Inc.
  • SK Chemicals Co., Ltd.
  • Vida Therapeutics Inc.

輻射性皮炎:治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

輻射性皮炎:最近的開發平台趨勢

輻射性皮炎:暫停中的計劃

輻射性皮炎:開發中止的產品

輻射性皮炎:產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8684IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Radiodermatitis - Pipeline Review, H2 2016, provides an overview of the Radiodermatitis (Dermatology) pipeline landscape.

Radiodermatitis is an inflammation of the skin caused by radiation. Several factors can be attributed to the varying response of patients' skin to radiation therapy such as treatment-related factors such as individual fraction size, type of energy, and the use of bolus doses can impact skin reactions. Host factors also may play a role in the development of radiodermatitis; they include genetic factors, personal factors, existing skin integrity issues, comorbid conditions, nutritional status, age, race and ethnicity, medications, sun exposure, smoking, and mobility.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Radiodermatitis - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Radiodermatitis (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Radiodermatitis (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Radiodermatitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 1, 1 and 3 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.Radiodermatitis.

Radiodermatitis (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Radiodermatitis (Dermatology).
  • The pipeline guide reviews pipeline therapeutics for Radiodermatitis (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Radiodermatitis (Dermatology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Radiodermatitis (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Radiodermatitis (Dermatology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Radiodermatitis (Dermatology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Radiodermatitis (Dermatology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Radiodermatitis Overview
  • Therapeutics Development
    • Pipeline Products for Radiodermatitis - Overview
    • Pipeline Products for Radiodermatitis - Comparative Analysis
  • Radiodermatitis - Therapeutics under Development by Companies
  • Radiodermatitis - Therapeutics under Investigation by Universities/Institutes
  • Radiodermatitis - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Radiodermatitis - Products under Development by Companies
  • Radiodermatitis - Products under Investigation by Universities/Institutes
  • Radiodermatitis - Companies Involved in Therapeutics Development
    • Reata Pharmaceuticals, Inc.
    • SK Chemicals Co., Ltd.
    • viDA Therapeutics Inc
  • Radiodermatitis - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • cerium oxide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Drug to Antagonize Adenosine A2A Receptor for Radiation Dermatitis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • omaveloxolone - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SKI-2162 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ST-266 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VTI-1000 Series - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Radiodermatitis - Dormant Projects
  • Radiodermatitis - Discontinued Products
  • Radiodermatitis - Product Development Milestones
    • Featured News & Press Releases
      • Jul 25, 2014: Reata Enrolls First Patient in the PRIMROSE Study, a Phase 2 Study Examining RTA 408 in Breast Cancer Patients at Risk for Radiation Dermatitis
      • Apr 24, 2014: RTA 408 Lotion Demonstrates Favorable Safety and Pharmacodynamic Response in a Phase 1 Study
      • Apr 10, 2014: Preclinical Study of Reata's RTA 408 Demonstrates Role in Prevention and Treatment of Radiation Dermatitis
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Radiodermatitis, H2 2016
  • Number of Products under Development for Radiodermatitis - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Radiodermatitis - Pipeline by Reata Pharmaceuticals, Inc., H2 2016
  • Radiodermatitis - Pipeline by SK Chemicals Co., Ltd., H2 2016
  • Radiodermatitis - Pipeline by viDA Therapeutics Inc, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Radiodermatitis - Dormant Projects, H2 2016
  • Radiodermatitis - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Radiodermatitis, H2 2016
  • Number of Products under Development for Radiodermatitis - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top